Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor.

Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint inhibitor followed by a combination of ipilimumab plus nivolumab were included in the study. The objective response rate was 20%, and the median progression-free survival was 4 months.

The combination of ipilimumab and nivolumab after treatment with an immune checkpoint inhibitor is effective in these patients, but prospective data are needed to confirm the results.

Read more in the Journal of Clinical Oncology here

Share this Post!


Related post

  TOP